# Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

> **NCT04878731** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Severe Hemophilia

## Interventions

- **BIOLOGICAL:** PF-06741086

## Key facts

- **NCT ID:** NCT04878731
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-16
- **Primary completion:** 2021-08-10
- **Final completion:** 2021-08-10
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04878731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04878731, "Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04878731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*